Yes but the experiments are already done… and importantly, done using the Flaskworks’ Edens.
They did NOT say that.
We know as fact that the Flaskworks team has experience analyzing characteristics of DCs. So they would be the logical team to do this. As the process would be new, it would be normal to do it manually until established.
Also, did you catch were they are saying Advent was looking into refurbishing the TTF equipment from a dozen years ago or finding a commercial alternative for manufacturing? Does that not clearly imply Eden is out for Direct manufacturing?>
On the timeline (for Direct), sure, evaluate the data and likely pull the trigger on that could be soon. But there is still a lot to do They still have to do some preclinical work and also creating the manufacturing process. I would be stunned if any Direct patient is dosed next year.
Market Data 
Markets 
